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Acute kidney injury: challenges 
for therapy development
Acute kidney injury (AKI) remains a seri-
ous complication in hospitalized patients, 
especially those that are critically ill (1, 
2), and results in significant mortality 
and morbidity in this population. Those 
individuals that develop AKI and survive 
are at extremely high risk of progressing 
to chronic kidney disease. AKI is almost 
invariably diagnosed in conjunction with 
a set of comorbid conditions, such as mul-
tiorgan sepsis or congestive heart failure, 
or in the aftermath of major cardiotho-
racic surgery. Basic research on AKI is 
complicated by the challenge of isolating 
and dissecting the mechanisms of AKI 
in animal or in vitro models while retain-
ing relevance to the typically complicated 
clinical presentation seen in patients in 
the ICU. This fundamental challenge 
has limited progress in the identification 
of novel preventative measures or treat-
ments for AKI that might improve upon 
the largely supportive measures that are 
currently employed (3). Researchers, phy-
sicians, and patients could sorely use some 
serendipitous findings that, like those of 
the three princes of Serendip (4), might 
advance their quest and put an end to their 
wanderings in search of an answer.
In this issue, Inoue, Abe, and col-
leagues (5) build on just such a finding and 
suggest a new path forward. Specifically, 
these authors have uncovered neuroim-
munomodulatory mechanisms that are 
amenable to therapeutic intervention and 
have potential to contribute additional 
strategies for limiting AKI. This line of 
research by Mark Okusa and colleagues 
began (6) with the hypothesis that precon-
ditioning the renal vasculature with con-
trast-enhanced ultrasound would stimu-
late increased blood flow to the kidney and 
thereby attenuate ischemia-reperfusion 
injury (IRI) and consequent AKI. Surpris-
ingly, the amelioration of IRI by prior 
ultrasound exposure did not require the 
introduction of contrast, nor did it require 
that the kidney itself be targeted with the 
ultrasound probe. Instead, exposure of 
the spleen was determined to be key to 
the protective effect, and a correlation 
between spleen enlargement and the abil-
ity to recruit CD4+ T cells to the spleen was 
found. Together, these results suggested 
that ultrasound stimulation might invoke 
an antiinflammatory response, leading 
Okusa and colleagues to propose that this 
protective effect was due to the known 
ability of certain ultrasound frequen-
cies to stimulate nerves. The proposed 
mechanism of action (Figure 1) involves 
ultrasound activation of adrenergic neu-
rons innervating the spleen, stimulation 
of CD4+ cells via β-adrenergic receptors, 
consequent release of acetylcholine by 
T cells, and then stimulation of nicotinic 
cholinergic receptors on myeloid/macro-
phage cells. Pharmacologic studies have 
implicated stimulation of α7 nicotinic 
acetylcholine receptors (α7nAChRs) pres-
ent on the myeloid cells in promoting an 
antiinflammatory response by these cells 
(7). Subsequent work from the Okusa lab 
(8) showed that the protective effect of 
ultrasound did indeed require innervation 
from the splenic nerve and was accom-
panied by attenuation of circulating and 
renal IL-6 in the setting of IRI. Moreover, 
the beneficial effect of ultrasound stimu-
lation on myeloid cells in treated animals 
was persistent over several days and suffi-
ciently durable to convey protection from 
IRI to ultrasound-naive animals that had 
received myeloid cells from ultrasound-
stimulated animals. The protective effect 
of ultrasound also decreased severe sepsis-
induced AKI in a mouse model. This latter 
observation of protection in a distinct (and 
clinically important) kidney injury model 
is particularly encouraging, as many inter-
ventions that have been shown to be effec-
tive in a single rodent AKI model have 
not proved to be clinically useful. Overall, 
these studies established the previously 
described cholinergic antiinflammatory 
pathway (CAP) (9) as the central mecha-
nism of protection conferred by ultra-
sound stimulation.
Vagus nerve stimulation–
mediated protection from IRI
While these observations are promising, 
questions remain as to how best to both 
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Acute kidney injury (AKI) is a common cause of hospital-related mortality; 
therefore, strategies to either prevent or treat this complication are of great 
interest. In this issue of the JCI, Inoue, Abe, and colleagues have uncovered 
a targetable neuroimmunomodulatory mechanism that protects mice 
from ischemia-reperfusion injury (IRI) and subsequent AKI. Specifically, 
the authors demonstrate that vagus nerve stimulation (VNS) activates 
the cholinergic antiinflammatory pathway (CAP), resulting in activation of 
antiinflammatory effects via α7 nicotinic acetylcholine receptor–expressing 
splenic macrophages. Together, the results of this study have potential 
clinical implications in the prevention of AKI in at-risk individuals.
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tiorgan failure, such neural mechanisms 
are likely to be even more important. This 
is a relatively neglected aspect of AKI and 
one that, as this new work clearly demon-
strates, deserves much more attention.
Conclusions and future 
directions
The effectiveness of VNS and ultrasound 
in mouse models is promising for further 
development of a practical preventative 
clinical strategy to reduce the incidence 
of AKI. Unfortunately, the ability of such 
an approach to treat AKI that has already 
started to progress is not a likely out-
come, as the protective effect of neuro-
immunomodulation only developed after 
a significant delay — VNS was effective 
at attenuating AKI when delivered at 24 
hours but not at 2 hours prior to injury (5). 
Therefore, the most likely clinical use for 
this approach would be as a prophylactic 
measure in situations where the patient is 
at high risk of developing AKI. In favor of 
neuroimmunomodulation as a preventa-
tive strategy is that the treatment itself, 
VNS or ultrasound (the ultrasound modal-
ity used in these studies generates little 
heat in the target tissues), is either nonin-
vasive or minimally invasive, and there is 
minimal risk from either procedure itself. 
Given the risk and benefit profile of this 
strategy, one could imagine this approach 
being employed widely in critical care set-
tings to reduce the risk of the serious con-
sequences of AKI, analogously to the pro-
vision of vaccines as low-risk preventative 
measures against infectious diseases.
in the splenic nerve, as initially thought 
(11). Moreover, vagal stimulation does not 
produce an evoked response in the splenic 
nerve, indicating that a vagal-vagal reflex 
is unlikely to be a central mechanism of 
CAP activation. Indeed, other data gener-
ated by Inoue, Abe, and colleagues point to 
more complex mechanisms, including the 
observation that left VNS remains protec-
tive even when the right vagal efferents are 
blocked during stimulation (5). This points 
to vagosympathetic reflex involvement or 
a hormonal axis.
More broadly, the studies from the 
Okusa lab point to the underappreciated 
importance of neuroimmunomodulatory 
mechanisms in AKI. Indeed, the AKI lit-
erature is replete with evidence that inter-
organ effects are important for disease 
development, even in simplistic models 
of AKI, such as the commonly employed 
renal artery clamp IRI model (3). This 
interorgan crosstalk is exemplified by the 
way that injury to one kidney profoundly 
affects the response of the other, contra-
lateral kidney (see, for example, ref. 12). 
Interorgan trafficking of immune cells and 
dissemination of inflammatory cytokines 
are surely responsible for many of these 
effects, but the present study by Inoue, 
Abe et al. again reinforces the view that 
neural mechanisms are also likely to con-
tribute in important ways to this phenom-
enon (5). Indeed, in the course of their 
study, the authors replicated the previous 
observation (13) that renal sympathetic 
denervation profoundly decreases injury 
in one model of IRI. In the setting of mul-
extend these findings to a therapeutic 
intervention that could be implemented 
in clinical practice and to uncover the pre-
cise neural mechanisms involved. Vagus 
nerve stimulation (VNS), in which a pat-
tern of electrical stimulation is delivered 
to the vagus nerve from a pulse generator 
implanted in the chest (with noninvasive 
transcutaneous devices in development), 
is approved for treatment of epilepsy and 
depression (10). Studies in animal models 
to evaluate the use of VNS in brain and 
heart IRI, for example, suggest that this 
strategy is capable of activating the CAP 
reflex (7). In this issue, Inoue, Abe, and 
colleagues (5) tested to determine whether 
VNS could produce protective effects simi-
lar to those induced by ultrasound stimula-
tion of the spleen. The results of this study 
confirm that VNS ameliorates IRI in the 
kidney and that the effect depends on the 
same CAP reflex pathway that is activated 
by ultrasound.
An interesting finding of the study by 
Inoue, Abe, et al. was that stimulation of 
either vagal afferents or efferents is suf-
ficient to confer protection (5). Addition-
ally, activation of vagal afferents on the 
left-hand side stimulated efferents on the 
right. Inoue, Abe, et al. suggest that vagal 
efferents could, therefore, be the common 
pathway that activates the CAP. Their data 
add more information to ongoing efforts to 
understand the neural pathways involved 
in the CAP, which does not appear to oper-
ate via a simple reflex arc of vagal effer-
ents forming synaptic connections with 
the noradrenergic postganglionic neurons 
Figure 1. Activation of the CAP by ultrasound or VNS attenuates IRI. Both VNS and ultrasound prior to IRI in murine models protect against the 
development of AKI. This protective effect is mediated by the integration of neural signals and α7nAChR on splenic macrophages. In addition to 
reducing AKI, VNS also reduced plasma levels of the proinflammatory cytokine TNF-α. Adapted with permission from the Journal of the American 
Society of Nephrology (6).
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splenic neuroimmune axis in attenuating AKI.  
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